E.a.s.e. rcc study
Conditions: Renal Cell Carcinoma Interventions: Other: active surveillance; Genetic: molecular investigation Sponsors: Azienda Ospedaliero Universitaria Maggiore della Carita; Universit à degli Studi del Piemonte Orientale " Amedeo Avogadro " Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials

Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors
Conditions: Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC); Renal Cell Carcinoma(RCC); Urothelial Carcinoma; Malignant Melanoma Interventions: Drug: LB-LR1109 Sponsors: LG Chem Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials

Abscopal Effects of Stereotactic Body Radiotherapy in Metastatic Clear Renal Cell Carcinoma
Conditions: Abscopal Effects of Stereotactic Body Radiotherapy Sponsors: Nanfang Hospital, Southern Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials

A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma Metastatic Interventions: Drug: JMKX003948 Sponsors: Jemincare; Zhejiang Hangyu Pharmaceutical Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials

Evaluation of the Safety of Reoperation for Ipsilateral Recurrent Tumors After Nephron-sparing Partial Nephrectomy
Conditions: Renal Cell Carcinoma; Robotic Surgical Procedures Sponsors: The First Affiliated Hospital of Anhui Medical University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 19, 2024 Category: Research Source Type: clinical trials

A Phase 0 Pilot Study of Memory-like Natural Killer (NK) Cell Immune Therapy in Combination With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
Conditions: Renal Carcinoma; Renal Cell Carcinoma; Urothelial Carcinoma Interventions: Biological: Cytokine Induced Memory-like Natural Killer (CIML NK) Cells; Biological: N-803 Sponsors: Dana-Farber Cancer Institute; Kidney Cancer Association; ImmunityBio, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 19, 2024 Category: Research Source Type: clinical trials

Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy
Conditions: Renal Cell Carcinoma, Clear Cell, Somatic Interventions: Drug: Fruquintinib and Everolimus Sponsors: Peking University First Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 19, 2024 Category: Research Source Type: clinical trials

A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004)
Conditions: Renal Cell Carcinoma Interventions: Biological: V940; Biological: Pembrolizumab; Biological: Placebo Sponsors: Merck Sharp& Dohme LLC; ModernaTX, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 12, 2024 Category: Research Source Type: clinical trials

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Conditions: Ovarian Carcinoma; Fallopian Tube Carcinoma; Peritoneal Carcinoma; Endometrial Cancer; Adenocarcinoma of Lung; Triple Negative Breast Cancer; Liposarcoma; Leiomyosarcoma; Mesothelioma, Malignant; Adenocarcinoma - Gastroesophageal Junction (GEJ); Adenocarcinoma of the Stomach; Melanoma, Malignant; Renal Cell Carcinoma Interventions: Biological: NM32-2668 Sponsors: Numab Therapeutics AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
Conditions: Metastatic Renal Cell Carcinoma Interventions: Drug: Evolocumab; Drug: Nivolumab Sponsors: M.D. Anderson Cancer Center; Bristol-Myers Squibb; Cancer Prevention Research Institute of Texas; United States Department of Defense Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials

A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Conditions: Neoplasms; Non-small-cell Lung Cancer; Melanoma; Squamous Cell Carcinoma of the Head and Neck; Renal Cell Carcinoma; Urothelial Carcinoma; Colorectal Carcinoma; Ovarian Carcinoma Interventions: Drug: PF-07820435; Biological: Sasanlimab Sponsors: Pfizer Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials

Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Conditions: Clear-cell Metastatic Renal Cell Carcinoma; Immune Checkpoint Inhibitors; Cytoreductive Nephrectomy Interventions: Drug: Toripalimab; Procedure: Cytoreductive Nephrectomy; Drug: Axitinib Sponsors: RenJi Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials

Resection or Ablation of Small Kidney Tumors
Conditions: Kidney Cancer Interventions: Procedure: Ablation; Procedure: Surgery Sponsors: Karolinska University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials

Prospective Evaluation of AI R & D Tool for Patient Stratification: a Trial for Renal Immuno-oncology Model Experimental Evaluation 2
Conditions: Kidney Cancer; Renal Cell Cancer Metastatic Interventions: Procedure: Biopsy Sponsors: Ourotech, Inc.; Royal Free Hospital NHS Foundation Trust; Cambridge University Hospitals NHS Trust; East& North Herts NHS Trust; Imperial College Healthcare NHS Trust Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Conditions: Head and Neck Cancer; Malignant Melanoma; Colorectal Cancer; Renal Cell Carcinoma; Cervical Cancer; Breast Cancer Interventions: Drug: GM103 (Part A); Drug: GM103 (Part B); Drug: GM103 and Pembrolizumab (Part C) Sponsors: GeneMedicine Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials